APL-3007, pegcetacoplan (APL-2) Clinical Trials (2026): 1 Studies for Geographic Atrophy Secondary to Age-related Macular Degeneration
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 APL-3007, pegcetacoplan (APL-2) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Geographic Atrophy Secondary to Age-related Macular Degeneration) and 240 total planned enrollment. 1 APL-3007, pegcetacoplan (APL-2) clinical trial is actively recruiting at 68 U.S. sites across 24 states. Most recent activity: NCT07215390 (Nov 2027).
Where to Participate: All APL-3007, pegcetacoplan (APL-2) Trial Sites in the U.S. (68 sites across 24 states)
Every actively recruiting APL-3007, pegcetacoplan (APL-2)trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Associated Retina Consultants (01065) | Gilbert85297 | NCT07215390 | Map |
| AZ | Barnet Dulaney Perkins Eye Center (01018) | Mesa85206 | NCT07215390 | Map |
| AZ | Associated Retina Consultants - Phoenix | Phoenix85020 | NCT07215390 | Map |
| AZ | Retinal Research Institute, LLC (01021) | Phoenix85053 | NCT07215390 | Map |
| CA | California Retina Consultants (CRC) - Bakersfield Office | Bakersfield93309 | NCT07215390 | Map |
| CA | The Retina Partners - Encino | Encino07003 | NCT07215390 | Map |
| CA | Retina Consultants of Orange County - Fullerton Office | Fullerton93825 | NCT07215390 | Map |
| CA | Salehi Retina Institute, Inc dba Retina Associate or Southern California (01034) | Huntington Beach92647 | NCT07215390 | Map |
| CA | Salehi Retina Institute, Inc. Dba Retina Associates of Southern California (01034) | Huntington Beach92647 | NCT07215390 | Map |
| CA | California Retina Consultants (01054) | Oxnard93036 | NCT07215390 | Map |
| CA | Retina Consultants San Diego | Poway92064 | NCT07215390 | Map |
| CA | Orange County Retina Medical Group | Santa Ana92705 | NCT07215390 | Map |
| CA | Bay Area Retina Associates - Walnut Creek | Walnut Creek94598 | NCT07215390 | Map |
| CO | Colorado Retina Associates, PLLC | Lakewood80228 | NCT07215390 | Map |
| CO | Advanced Vision Research Institute | Longmont80503 | NCT07215390 | Map |
| CT | Connecticut Eye Consultants, PC (01074) | Danbury06810 | NCT07215390 | Map |
| FL | ClearVista Clinical Research, LLC (01096) | Bayonet Point34667 | NCT07215390 | Map |
| FL | Florida Retina Institute - Orlando (01053) | Orlando32806 | NCT07215390 | Map |
| FL | Florida Retina Institute (01053) | Orlando32806 | NCT07215390 | Map |
| FL | Retina Specialty Institute - Pensacola | Pensacola32503 | NCT07215390 | Map |
| FL | Eye Associates of Pinellas (01020) | Pinellas Park33782 | NCT07215390 | Map |
| FL | Retina Vitreous Associates of Florida (RVA) - Saint Petersburg | St. Petersburg33711 | NCT07215390 | Map |
| FL | Center for Retina and Macular Disease (01026) | Winter Haven33880 | NCT07215390 | Map |
| GA | Southeast Retina Center | Augusta30909 | NCT07215390 | Map |
| IL | Illinois Retina Associates, S.C. - Oak Park (01061) | Oak Park60304 | NCT07215390 | Map |
| IN | Midwest Eye Institute (01066) | Carmel46032 | NCT07215390 | Map |
| IN | Advancing Research International. LLC (01090) | Indianapolis46214 | NCT07215390 | Map |
| IN | Retina Consultants P.C. | Indianapolis46214 | NCT07215390 | Map |
| LA | Retina Associates New Orleans - Jefferson Parish Location | Metairie70001 | NCT07215390 | Map |
| MD | The Retina Group of Washington (01089) | Chevy Chase29902 | NCT07215390 | Map |
| MD | Cumberland Valley Retina Consultants (CVRC) | Hagerstown21740 | NCT07215390 | Map |
| MS | Mississippi Retina Associates | Madison39110 | NCT07215390 | Map |
| NJ | Envision Ocular, LLC (01027) | Bloomfield07003 | NCT07215390 | Map |
| NJ | Mid Atlantic Retina (01039) | Cherry Hill08034 | NCT07215390 | Map |
| NJ | NJ Retina (01031) | Edison08820 | NCT07215390 | Map |
| NJ | NJ Retina (01030) | Toms River08755 | NCT07215390 | Map |
| NM | Vision Research Center Eye Associates of New Mexico (01023) | Albuquerque87109 | NCT07215390 | Map |
| NY | Long Island Vitreoretinal Consultants (01050) | Great Neck11021 | NCT07215390 | Map |
| NY | Long Island Vitreoretinal Consultants - Westbury | Long Island City11590 | NCT07215390 | Map |
| OH | Retina Assocaites of Cleveland, Inc (01048) | Cleveland44122 | NCT07215390 | Map |
| OR | Verum Research, LLC | Eugene97401 | NCT07215390 | Map |
| OR | EyeHealth Northwest | Portland97225 | NCT07215390 | Map |
| OR | EyeHealth Northwest (01006) | Portland97228 | NCT07215390 | Map |
| OR | Cascade Medical Research Institute, LLC (01070) | Springfield97477 | NCT07215390 | Map |
| PA | Mid Atlantic Retina - Philadelphia (01017) | Philadelphia19107 | NCT07215390 | Map |
| SC | Charleston Neuroscience Institute (01037) | Beaufort29902 | NCT07215390 | Map |
| SC | Retina Consultants of Carolina, PA (01073) | Greenville29605 | NCT07215390 | Map |
| SC | Charleston Neuroscience Institute LLC - Ladson | Ladson29456 | NCT07215390 | Map |
| SC | Charleston Neuroscience Institute, LLC - Mount Pleasant (01051) | Mt. Pleasant29464 | NCT07215390 | Map |
| SD | Ophthalmology Ltd. (01084) | Sioux Falls57108 | NCT07215390 | Map |
| TN | Tennessee Retina, PC (01063) | Nashville37203 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - Abilene (01035) | Abilene79606 | NCT07215390 | Map |
| TX | Austin Retina Associates | Austin78705 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - Bellaire (01067) | Bellaire77401 | NCT07215390 | Map |
| TX | Texas Retina Associates | Dallas75231 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - Katy | Katy77494 | NCT07215390 | Map |
| TX | Valley Retina Institute- McAllen (01076) | McAllen78503 | NCT07215390 | Map |
| TX | Austin Retina Associates - Round Rock (01032) | Round Rock78681 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - San Antonio Medical Center | San Antonio78240 | NCT07215390 | Map |
| TX | Austin Retina Associate (01046) | San Marcos78666 | NCT07215390 | Map |
| TX | Retina Consultants of Texas (01055) | Schertz78154 | NCT07215390 | Map |
| TX | Retina Center of Texas - Southlake | Southlake76092 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - The Woodlands | The Woodlands73384 | NCT07215390 | Map |
| TX | Tyler Retina Consultants | Tyler75703 | NCT07215390 | Map |
| UT | Retina Associates of Utah (01052) | Salt Lake City84107 | NCT07215390 | Map |
| UT | Salt Lake Retina (01044) | West Jordan84088 | NCT07215390 | Map |
| VA | Piedmont Eye Center (01097) | Lynchburg24502 | NCT07215390 | Map |
| WI | University of Wisconsin Health - University Station Clinic | Madison53705 | NCT07215390 | Map |
APL-3007, pegcetacoplan (APL-2) clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting APL-3007, pegcetacoplan (APL-2) clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07215390 | APL-2A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | P2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | 240 | Jun 2025 |
APL-3007, pegcetacoplan (APL-2) pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| APL-2 | NCT07215390 | P2 | recruiting | Geographic Atrophy Secondary to Age-related Macular Degeneration | 240 | — |
All APL-3007, pegcetacoplan (APL-2) trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07215390 | APL-2 | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | P2 | recruiting | 240 | Apellis Pharmaceuticals, Inc. | Jun 2025 |
APL-3007, pegcetacoplan (APL-2) clinical trials: frequently asked questions
- How many APL-3007, pegcetacoplan (APL-2) clinical trials are there?
- 1 APL-3007, pegcetacoplan (APL-2) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are APL-3007, pegcetacoplan (APL-2) clinical trials recruiting in 2026?
- Yes — 1 APL-3007, pegcetacoplan (APL-2) trial is actively recruiting in 2026, with 68 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is APL-3007, pegcetacoplan (APL-2) being studied for?
- APL-3007, pegcetacoplan (APL-2) is being studied for Geographic Atrophy Secondary to Age-related Macular Degeneration. The trials are grouped by indication on this page.
- What phase is APL-3007, pegcetacoplan (APL-2) in?
- APL-3007, pegcetacoplan (APL-2) clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors APL-3007, pegcetacoplan (APL-2) clinical trials?
- The lead sponsor across the most APL-3007, pegcetacoplan (APL-2) trials is Apellis Pharmaceuticals, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming APL-3007, pegcetacoplan (APL-2)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: